Proof of Concept in Patients with Generalized Anxiety Disorder (GAD)AZD7325

Study identifier:D1140C00014

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase II Study of 2 Oral Dose Groups of AZD7325, with a Lorazepam Arm, in Subjects with Generalized Anxiety Disorder (GAD)

Medical condition

Anxiety Disorders

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD7325, Lorazepam, Placebo

Sex

All

Actual Enrollment

369

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Dec 2008
Primary Completion Date: 01 May 2009
Study Completion Date: 01 May 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2010 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria